Issa F Khouri

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Nonmyeloablative allogeneic stem cell transplantation for non-hodgkin lymphoma
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer J 18:457-62. 2012
  2. ncbi request reprint Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, USA
    Cancer 117:4679-88. 2011
  3. doi request reprint Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 119:6373-8. 2012
  4. ncbi request reprint Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 111:5530-6. 2008
  5. ncbi request reprint Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 137:355-63. 2007
  6. doi request reprint Allogeneic stem cell transplantation in follicular lymphoma
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, Unit 423, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Best Pract Res Clin Haematol 24:271-7. 2011
  7. ncbi request reprint Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas
    Issa F Khouri
    Department of Blood and Marrow Transplantation, Unit 423, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 23:2240-7. 2005
  8. ncbi request reprint Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma
    Issa F Khouri
    Department of Blood and Marrow Transplantation, Unit 423, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 21:4407-12. 2003
  9. ncbi request reprint Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics
    I F Khouri
    Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 33:833-7. 2004
  10. ncbi request reprint High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma
    Chitra Hosing
    Department of Blood and Marrow Transplantation, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 47:1290-4. 2006

Collaborators

Detail Information

Publications52

  1. ncbi request reprint Nonmyeloablative allogeneic stem cell transplantation for non-hodgkin lymphoma
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer J 18:457-62. 2012
    ..Considerations for the conditioning regimen, donor source, graft-versus-host disease prophylaxis, donor lymphocyte infusion, and relapse prevention methods are reviewed...
  2. ncbi request reprint Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, USA
    Cancer 117:4679-88. 2011
    ..The authors report on long-term experience with NST in relapsed/refractory CLL and define prognostic factors associated with outcome...
  3. doi request reprint Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 119:6373-8. 2012
    ..The addition of (90)Y to the conditioning regimen appears to be effective in patients with chemorefractory disease. This trial was registered at www.clinicaltrials.gov as NCT00048737...
  4. ncbi request reprint Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 111:5530-6. 2008
    ..Only 5 patients were still undergoing immunosuppressive therapy at the time of last follow-up. We believe that the described results are a step forward toward developing a curative strategy for recurrent follicular lymphoma...
  5. ncbi request reprint Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 137:355-63. 2007
    ..These results demonstrate a potent graft-versus-leukaemia effect that can overcome the adverse prognostic effect of ZAP-70 expression...
  6. doi request reprint Allogeneic stem cell transplantation in follicular lymphoma
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, Unit 423, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Best Pract Res Clin Haematol 24:271-7. 2011
    ....
  7. ncbi request reprint Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas
    Issa F Khouri
    Department of Blood and Marrow Transplantation, Unit 423, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 23:2240-7. 2005
    ....
  8. ncbi request reprint Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma
    Issa F Khouri
    Department of Blood and Marrow Transplantation, Unit 423, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 21:4407-12. 2003
    ..Patients with relapsed mantle-cell lymphoma have poor prognosis and short survival. Our aim was to determine the efficacy of nonablative allogeneic stem-cell transplantation in patients with relapsed mantle-cell lymphoma...
  9. ncbi request reprint Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics
    I F Khouri
    Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 33:833-7. 2004
    ..At 3 months, 11 had achieved 100% donor chimerism. No cases of grade III/IV acute GVHD occurred. At a median follow-up interval of 14.7 months (range 4-24), seven patients remained alive, and five remained free of disease...
  10. ncbi request reprint High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma
    Chitra Hosing
    Department of Blood and Marrow Transplantation, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 47:1290-4. 2006
    ..In conclusion, high-dose rituximab given during stem cell mobilization does not negatively affect stem cell mobilization kinetics...
  11. doi request reprint Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience
    Paolo Anderlini
    The U T M D Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030 USA
    Haematologica 93:257-64. 2008
    ..We here present an update of our single-center experience with fludarabine-melphalan as a preparative regimen...
  12. ncbi request reprint Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia
    Partow Kebriaei
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 110:3456-62. 2007
    ..TRM rates are acceptable in this high-risk population but increase over time...
  13. doi request reprint Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission
    Zaher I Chakhachiro
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer 119:3318-25. 2013
    ....
  14. ncbi request reprint Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors
    Naoto T Ueno
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 448, Houston, TX 77030, USA
    Blood 102:3829-36. 2003
    ..It induces rapid complete donor chimerism without the need for donor lymphocyte infusion. Tumor regression associated with GVHD is consistent with graft-versus-tumor effect...
  15. ncbi request reprint Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer
    Yee Chung Cheng
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Hematol 90:627-34. 2009
    ..Estimated 3-year progression-free and overall survival rates were 31 and 57%. Our study suggested that the use of IL-2 and growth factors immunomodulation with HDC/AHST was feasible with comparable survival rates...
  16. ncbi request reprint Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation
    Maricer P Escalon
    Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:2419-23. 2004
    ..We investigated the safety and efficacy of nonmyeloablative stem-cell transplantation in these patients...
  17. ncbi request reprint Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation
    Amin M Alousi
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 142:786-92. 2008
    ..We conclude that evidence of disease on PET/G scanning prior to transplantation is associated with an increased risk for relapse after ASCT. Transplantation regimens containing rituximab can reduce this risk, regardless of PET/G status...
  18. ncbi request reprint Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score
    Issa F Khouri
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas
    Cancer 98:2630-5. 2003
    ..The current study was conducted to analyze the long-term results of autologous stem cell transplantation (ASCT) in patients with diffuse mantle cell lymphoma (MCL) in first disease remission...
  19. ncbi request reprint Nonmyeloablative stem cell transplantation for lymphoma
    Issa F Khouri
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 31:22-6. 2004
    ..Results from these trials confirm the full potential on nonmyeloablative transplantation for patients with NHL...
  20. ncbi request reprint Hyperacute GVHD: risk factors, outcomes, and clinical implications
    Rima M Saliba
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 109:2751-8. 2007
    ..In conclusion, hyperacute GVHD accounts for a substantial proportion of grade II-IV acute GVHD after HSCT. Patients at high risk or with a diagnosis of hyperacute GVHD should be included in clinical studies...
  21. ncbi request reprint Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival
    Issa F Khouri
    Department of Blood and Marrow Transplantation, M D Anderson Cancer Center, Houston, Tex 77030, USA
    Exp Hematol 32:28-35. 2004
    ..To investigate the graft-vs-leukemia effect of allogeneic stem cell transplantation after a nonablative conditioning regimen as treatment for patients with chronic lymphocytic leukemia...
  22. ncbi request reprint Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation
    Malisha R Johnson
    Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Ann Diagn Pathol 10:263-8. 2006
    ..Of 4 cases, 3 had complex karyotypes, including the t(11;14)(q13;q32) or del(11)(q13). Despite chemotherapy and the use of novel therapeutic agents and stem cell transplantation, all 4 patients had short survival...
  23. ncbi request reprint Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome
    Gheath Alatrash
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 17:1841-5. 2011
    ....
  24. ncbi request reprint Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality
    I F Khouri
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Blood 98:3595-9. 2001
    ..Further studies are warranted to compare nonablative allogeneic hematopoietic transplantation with alternative treatment strategies...
  25. ncbi request reprint Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis
    Martin Korbling
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Transfusion 46:1795-802. 2006
    ..This study provides clinical data on the availability of circulating EPCs at steady state and after recombinant human granulocyte-colony-stimulating factor (rHuG-CSF) mobilization and their collection by leukapheresis...
  26. pmc Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies
    Carlos A Ramos
    Department of Stem Cell, Transplantation and Cellular Therapy, The University of Texas M D, Anderson Cancer Center 1515 Holcombe Blvd, Unit 423, Houston, TX 77030, USA
    Haematologica 94:249-57. 2009
    ....
  27. ncbi request reprint Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
    I F Khouri
    Department of Hematology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:2817-24. 1998
    ....
  28. ncbi request reprint Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission
    Betul Oran
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 19:214-20. 2013
    ..These patients should be considered for clinical trials designed to optimize conditioning regimens and/or to use preemptive strategies in the posttransplantion setting aimed at decreasing RI...
  29. ncbi request reprint Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization
    James L Gajewski
    University of Texas M D Anderson Cancer Center, Department of Blood and Marrow Transplantation, Houston 77030 4095, USA
    Biol Blood Marrow Transplant 8:550-6. 2002
    ..Further studies are also warranted in patients who are likely to experience suboptimal PBPC mobilization when treated with currently available techniques...
  30. ncbi request reprint Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy
    I F Khouri
    Department of Blood and Marrow Transplantation, University of Texas, M D Anderson Cancer Center, Houston, USA
    Ann Oncol 10:1293-9. 1999
    ..We report preliminary results suggestive of a graft-versus-lymphoma effect in such patients post allogeneic hematopoietic transplantation...
  31. ncbi request reprint Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma
    U Popat
    Department of Blood and Marrow Transplant, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Bone Marrow Transplant 33:1015-23. 2004
    ..We conclude that autologous transplantation is an effective salvage treatment for recurrent HL...
  32. ncbi request reprint Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1
    D Przepiorka
    Baylor College of Medicine Center for Cell and Gene Therapy, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 6:190-7. 2000
    ..02), but overall survival at day 180 did not differ significantly among the 3 groups. Tacrolimus does not abrogate the adverse impact of allele mismatching at HLA-DRB1 and HLA-DQB1 on the risk of moderate-to-severe acute GVHD...
  33. ncbi request reprint Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma
    I F Khouri
    Department of Hematology, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:3803-9. 1998
    ..After four courses, patients were consolidated with high-dose CY, total-body irradiation, and autologous or allogeneic blood or marrow stem-cell transplantation...
  34. ncbi request reprint Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation
    I F Khouri
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Center, Houston, TX 77030, USA
    Cytotherapy 4:217-21. 2002
    ..We investigated the long-term outcome of allogeneic stem-cell transplantation after myeloablative conditioning regimen as treatment for patients with chronic lymphocytic leukemia...
  35. ncbi request reprint Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies
    L Lekakis
    Department of Blood and Marrow Transplantation, UT MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Bone Marrow Transplant 38:421-6. 2006
    ..Two patients are alive and disease free; 4-year actuarial survival is 33 versus 0% for patients transplanted in remission versus in relapse. We concluded that disease status was the main determinant of treatment failure in this study...
  36. ncbi request reprint Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer
    N T Ueno
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:986-93. 1998
    ..To evaluate the feasibility of allogeneic peripheral-blood progenitor-cell (PBPC) transplantation and to assess graft-versus-tumor effects in patients with metastatic breast cancer...
  37. ncbi request reprint Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies
    E Ozdemir
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Bone Marrow Transplant 40:125-36. 2007
    ..The remaining patients had an intermediate incidence of 32%...
  38. ncbi request reprint Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma
    C Hosing
    Departments of Blood and Marrow Transplantation and Lymphoma, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 14:737-44. 2003
    ..The aim of this study was to compare the outcomes of high-dose therapy (HDT) and allogeneic versus autologous hematopoietic stem cell transplantation (SCT) in patients with refractory or recurrent indolent non-Hodgkin's lymphoma (NHL)...
  39. ncbi request reprint High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation
    A Safdar
    Department of Infectious Diseases, Infection Control, and Employee Health, MD Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 39:157-64. 2007
    ..04) and/or interferon gamma (26 vs 5% in SD group; P=0.003) immune enhancement. Further studies are needed to evaluate efficacy of HD-CAP in severely immunosuppressed cancer patients with invasive fungal infections...
  40. ncbi request reprint Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia
    P Kebriaei
    Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 38:203-9. 2006
    ....
  41. ncbi request reprint Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response
    P Anderlini
    Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 34:511-4. 2004
    ..The small sample size does not allow any conclusion as to whether chemotherapy administration increases the chance of response. The CD3 cell dose infused does not seem to correlate with disease response...
  42. ncbi request reprint Evaluation of peripheral blood involvement of mantle cell lymphoma by fluorescence in situ hybridization in comparison with immunophenotypic and morphologic findings
    Jun Gu
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 17:553-60. 2004
    ....
  43. pmc Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma
    Yvonne A Efebera
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Biol Blood Marrow Transplant 16:1122-9. 2010
    ..The use of RIC allo-HSCT earlier in the course of the disease may offer the greatest benefit...
  44. ncbi request reprint Impact of high-dose chemotherapy on peripheral T-cell lymphomas
    J Rodriguez
    Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:3766-70. 2001
    ..Considering the dismal outcome of conventional chemotherapy in PTCL patients, these data suggest the hypothesis that the poor prognostic implication of T-cell phenotyping in NHL might be overcome by frontline HDCT and transplantation...
  45. ncbi request reprint Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma
    C Hosing
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Ann Oncol 13:450-9. 2002
    ....
  46. ncbi request reprint Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity
    R Gopal
    Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Cancer 92:1949-58. 2001
    ..The increased dose may contribute to a decrease in the recurrence rate in these patients. (c) 2001 American Cancer Society...
  47. ncbi request reprint Adult Henoch-schönlein purpura in a patient with myelodysplastic syndrome and a history of follicular lymphoma
    Matthew C Fox
    Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cutis 81:131-7. 2008
    ..To understand Henoch-Schönlein purpura (HSP) to better manage patients with the condition...
  48. ncbi request reprint Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease
    D R Couriel
    Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 130:409-17. 2005
    ..Controlled trials comparing this approach with alternative strategies to determine which can best achieve the goal of GVHD-free survival are warranted...
  49. ncbi request reprint Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation
    E Jabbour
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Bone Marrow Transplant 40:431-5. 2007
    ..Overall, we found that fludarabine and ATG conditioning before a second SCT allows engraftment of donor hematopoiesis. Future studies should include more intense GVHD prophylaxis...
  50. ncbi request reprint Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant?
    E Jabbour
    Department of Blood and Bone Marrow Transplant, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 34:289-97. 2004
    ..Randomized trials designed according to the new biologic prognostic parameters described in chronic lymphocytic leukemia are required to better define the role of NMA SCT in the near future...
  51. ncbi request reprint Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research
    Steven Z Pavletic
    Graft versus Host and Autoimmunity Unit, Experimental Transplantation and Immunology Branch, National Cancer Institute, 9000 Rockville Pike, Building 10, Room CRC 3 3330, Bethesda, MD 20892 1907, USA
    J Clin Oncol 23:5788-94. 2005
    ..To determine the role of myeloablative conditioning and unrelated donor (URD) bone marrow transplantation in the treatment of patients with advanced B-cell chronic lymphocytic leukemia (CLL)...
  52. ncbi request reprint Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome
    Alberto J Montero
    Hematology Oncology Division, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA
    Leuk Lymphoma 47:2049-54. 2006
    ..Our study provides additional clinical evidence that chronic administration of IL-11, at low doses, can raise platelet counts and reduce platelet transfusion requirements in a subset of patients with MDS...